About Tango Therapeutics, Inc.
https://www.tangotx.comTango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
CEO
Barbara L. Weber
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 102
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
TRV GP IV, LLC
Shares:13.86M
Value:$171.77M
FARALLON CAPITAL MANAGEMENT LLC
Shares:10.76M
Value:$133.28M
ECOR1 CAPITAL, LLC
Shares:10.63M
Value:$131.71M
Summary
Showing Top 3 of 153
About Tango Therapeutics, Inc.
https://www.tangotx.comTango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $53.81M ▲ | $39.18M ▼ | $15.88M ▲ | 29.52% ▲ | $0.14 ▲ | $16.43M ▲ |
| Q2-2025 | $3.18M ▼ | $43.52M ▼ | $-38.85M ▲ | -1.22K% ▼ | $-0.35 ▲ | $-38.19M ▲ |
| Q1-2025 | $5.39M ▲ | $47.92M ▲ | $-39.88M ▼ | -739.54% ▲ | $-0.36 ▼ | $-41.91M ▼ |
| Q4-2024 | $4.12M ▼ | $45.03M ▲ | $-37.67M ▼ | -914.99% ▼ | $-0.34 ▼ | $-40.29M ▼ |
| Q3-2024 | $11.61M | $44.48M | $-29.17M | -251.29% | $-0.27 | $-32.26M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $152.81M ▼ | $210.14M ▼ | $50.1M ▼ | $160.03M ▲ |
| Q2-2025 | $180.78M ▼ | $237.89M ▼ | $102.94M ▼ | $134.95M ▼ |
| Q1-2025 | $216.72M ▼ | $274.31M ▼ | $107.55M ▼ | $166.76M ▼ |
| Q4-2024 | $257.92M ▼ | $316.49M ▼ | $116.97M ▼ | $199.52M ▼ |
| Q3-2024 | $293.28M | $352.42M | $123.25M | $229.17M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $15.88M ▲ | $-30.95M ▲ | $47.48M ▲ | $2.54M ▲ | $19.07M ▲ | $-31.1M ▲ |
| Q2-2025 | $-38.85M ▲ | $-36.52M ▲ | $16.78M ▼ | $581K ▲ | $-19.16M ▼ | $-37.14M ▲ |
| Q1-2025 | $-39.88M ▼ | $-41.7M ▼ | $30.6M ▼ | $2K ▼ | $-11.1M ▼ | $-41.75M ▼ |
| Q4-2024 | $-37.67M ▼ | $-36.65M ▼ | $52.06M ▲ | $969K ▼ | $16.38M ▲ | $-36.77M ▼ |
| Q3-2024 | $-29.17M | $-33.39M | $32.57M | $2.4M | $1.58M | $-33.51M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaboration Revenue | $20.00M ▲ | $10.00M ▼ | $0 ▼ | $50.00M ▲ |
 License Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Barbara L. Weber
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 102
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
TRV GP IV, LLC
Shares:13.86M
Value:$171.77M
FARALLON CAPITAL MANAGEMENT LLC
Shares:10.76M
Value:$133.28M
ECOR1 CAPITAL, LLC
Shares:10.63M
Value:$131.71M
Summary
Showing Top 3 of 153